AMAG Pharmaceuticals, Inc. (AMAG) Shares Sold by Russell Investments Group Ltd.

Russell Investments Group Ltd. cut its position in shares of AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) by 1.9% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 564,965 shares of the specialty pharmaceutical company’s stock after selling 10,699 shares during the period. Russell Investments Group Ltd. owned approximately 1.61% of AMAG Pharmaceuticals worth $10,395,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in AMAG. State of Alaska Department of Revenue increased its position in shares of AMAG Pharmaceuticals by 81.3% in the second quarter. State of Alaska Department of Revenue now owns 6,871 shares of the specialty pharmaceutical company’s stock worth $126,000 after buying an additional 3,081 shares during the period. Advisors Asset Management Inc. increased its position in shares of AMAG Pharmaceuticals by 259.9% in the first quarter. Advisors Asset Management Inc. now owns 6,931 shares of the specialty pharmaceutical company’s stock worth $156,000 after buying an additional 5,005 shares during the period. Mason Street Advisors LLC increased its position in shares of AMAG Pharmaceuticals by 7.4% in the first quarter. Mason Street Advisors LLC now owns 8,030 shares of the specialty pharmaceutical company’s stock worth $181,000 after buying an additional 554 shares during the period. Sei Investments Co. increased its position in shares of AMAG Pharmaceuticals by 0.7% in the first quarter. Sei Investments Co. now owns 8,342 shares of the specialty pharmaceutical company’s stock worth $188,000 after buying an additional 54 shares during the period. Finally, Affinity Investment Advisors LLC increased its position in shares of AMAG Pharmaceuticals by 51.4% in the first quarter. Affinity Investment Advisors LLC now owns 9,747 shares of the specialty pharmaceutical company’s stock worth $220,000 after buying an additional 3,310 shares during the period.

Shares of AMAG Pharmaceuticals, Inc. (AMAG) traded down 1.44% during midday trading on Tuesday, reaching $17.10. The company’s stock had a trading volume of 105,616 shares. AMAG Pharmaceuticals, Inc. has a 1-year low of $16.00 and a 1-year high of $36.83. The company’s 50-day moving average price is $19.03 and its 200 day moving average price is $20.72. The firm’s market capitalization is $603.42 million.

AMAG Pharmaceuticals (NASDAQ:AMAG) last issued its earnings results on Thursday, August 3rd. The specialty pharmaceutical company reported ($0.40) EPS for the quarter, topping the consensus estimate of ($0.58) by $0.18. The company had revenue of $158.39 million during the quarter, compared to analyst estimates of $158.83 million. AMAG Pharmaceuticals had a negative return on equity of 4.81% and a negative net margin of 7.58%. The business’s revenue was up 24.3% on a year-over-year basis. During the same quarter last year, the firm earned $1.45 EPS. On average, equities research analysts forecast that AMAG Pharmaceuticals, Inc. will post ($1.37) earnings per share for the current year.

TRADEMARK VIOLATION NOTICE: “AMAG Pharmaceuticals, Inc. (AMAG) Shares Sold by Russell Investments Group Ltd.” was originally posted by Community Financial News and is the sole property of of Community Financial News. If you are accessing this article on another website, it was copied illegally and republished in violation of US and international copyright and trademark laws. The legal version of this article can be viewed at https://www.com-unik.info/2017/08/15/amag-pharmaceuticals-inc-amag-shares-sold-by-russell-investments-group-ltd.html.

A number of equities analysts recently issued reports on the company. Barclays PLC reaffirmed a “hold” rating and issued a $25.00 price target on shares of AMAG Pharmaceuticals in a report on Friday, May 5th. ValuEngine raised AMAG Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Tuesday, July 25th. TheStreet downgraded AMAG Pharmaceuticals from a “c” rating to a “d+” rating in a report on Friday, May 5th. Citigroup Inc. lowered their price target on AMAG Pharmaceuticals to $24.00 and set a “hold” rating for the company in a report on Friday, July 7th. Finally, Jefferies Group LLC set a $40.00 price target on AMAG Pharmaceuticals and gave the company a “buy” rating in a report on Thursday, April 20th. Two analysts have rated the stock with a sell rating, eleven have assigned a hold rating and two have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and a consensus target price of $28.09.

In other news, SVP Julie Krop sold 4,938 shares of AMAG Pharmaceuticals stock in a transaction that occurred on Thursday, July 13th. The stock was sold at an average price of $20.00, for a total value of $98,760.00. Following the completion of the transaction, the senior vice president now owns 28,336 shares in the company, valued at approximately $566,720. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. 3.80% of the stock is currently owned by company insiders.

About AMAG Pharmaceuticals

AMAG Pharmaceuticals, Inc is a pharmaceutical company. The Company’s segment is the manufacture, development and commercialization of products and services for use in treating various conditions, with a focus on maternal health, anemia management and cancer supportive care. Its offerings focus on maternal health, anemia management and cancer supportive care, including its product, Makena (hydroxyprogesterone caproate injection); services related to the collection, processing and storage of umbilical cord blood stem cell and cord tissue units operated through Cord Blood Registry (CBR); its product, Feraheme (ferumoxytol), for intravenous (IV) use, and MuGard Mucoadhesive Oral Wound Rinse.

Institutional Ownership by Quarter for AMAG Pharmaceuticals (NASDAQ:AMAG)

What are top analysts saying about AMAG Pharmaceuticals Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for AMAG Pharmaceuticals Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit